876513-92-7

Upstream product

• 1761-61-1 5-bromosalicyclaldehyde 
• 104-03-0 4-nitrobenzeneacetic acid 
• 280140-39-8 6-bromo-3-(4-nitrophenyl)-2H-chromen-2-one 

Downstream Products

• 887647-18-9 3-(4-aminophenyl)-6-(tributylstannyl)-2H-chromen-2-one 
• 887647-16-7 6-bromo-3-(4-(methylamino)phenyl)-2H-chromen-2-one 
• 887647-17-8 6-bromo-3-(4-(dimethylamino)phenyl)-2H-chromen-2-one 
• 887647-21-4 3-(4-(methylamino)phenyl)-6-(tributylstannyl)-2H-chromen-2-one 

Relevant academic research and scientific papers

Synthesis and biological evaluation of radioiodinated 3-phenylcoumarin derivatives targeting myelin in multiple sclerosis

Myelin is a lipid multilayer involved in the rate of nerve transmission, and its loss is a pathological feature of multiple sclerosis in brains. Since in vivo imaging of myelin may be useful for drug development, early diagnosis, and monitoring the disease stage, we designed, synthesized, and evaluated eight novel radioiodinated 3-phenylcoumarin derivatives as imaging probes targeting myelin. In the biodistribution study using normal mice, all compounds displayed sufficient brain uptake, ranging from 2.5 to 5.0% ID/g, at 2 min postinjection. On ex vivo autoradiography, [125I]18 and [125I]21, which have a dimethylamino group, showed high binding affinity for myelin in the normal mouse brain. In addition, the radioactivity accumulation of [125I]21 in the white matter of the spinal cord in the experimental autoimmune encephalomyelitis mice was lower than that in naive mice. These results suggest that [123I]21 shows potential as a single photon emission computed tomography probe targeting myelin.

COMPOUND FOR BORON NEUTRON CAPTURE THERAPY FOR AMYLOID β DISEASES

PROBLEM TO BE SOLVED: To provide a boron carrier compound having high binding specificity to an amyloid β protein, high permeability through the blood brain barrier, and a retention property in senile plaques in the brain, while having a property less lik

COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS

A composition for diagnosing amyloid-related diseases, which comprises a flavone derivative, a chalcone derivative, a styrylchromone derivative, or a coumarin derivative, is provided. These compounds have high binding specificity to an amyloid β protein,